Mycobacterium intracellulare Pulmonary Disease with Endobronchial Caseation in a Patient Treated with Methotrexate

Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jin Sun, Jung, Eul Sik, Choi, Woosuk, Park, Soo Yong, Rim, Min Young, Yu, Inku, Park, Hyeonsu, Lee, Sang Min, Park, Jeong-Woong, Jeong, Sung Hwan, Lee, Sang Pyo, Park, Sanghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741471/
https://www.ncbi.nlm.nih.gov/pubmed/23946756
http://dx.doi.org/10.4046/trd.2013.75.1.28
Descripción
Sumario:Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of a woman with rheumatoid arthritis taking MTX, and the woman developed actively caseating endobronchial Mycobacterium intracellulare disease with pulmonary infiltrations. After discontinuing the MTX, the patient was able to tolerate 18 months of antimycobacterial treatment without flare ups of rheumatoid arthritis, and she completely recovered from nontuberculous mycobacterial respiratory disease.

Ejemplares similares